Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
OwnerGustavo C. Rodriguezinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer by administering compounds in an amount capable of regulating TGF-β expression in the ovarian epithelium and/or capable of optimally altering expression of other surrogate biomarkers identified by microarray technology. HRT and OCP regimens comprising such compositions and methods are disclosed.
Claims33
A method for designing a pharmaceutical composition for reducing the risk of ovarian cancer comprising an agent, said method comprising obtaining information on said agent's ability to induce biologic effect to regulate TGF-β expression in the ovarian epithelium and selecting said agent after consideration of such information.
A pharmaceutical regimen comprising one or more agents, said regimen made by the process of considering of the ability of said one or more agents to upregulate expression of one or more TGF-β isoforms in the ovarian epithelium, considering the ability of said one or more agents to downregulate expression of one or more other TGF-β isoforms in the ovarian epithelium, and selecting said one or more agents after such consideration).
The regimen of 9 including a pulse of periodic dosages wherein said one or more one or more agents upregulate expression of one or more TGF-β isoforms in the ovarian epithelium to a greater extent during one portion of the regimen than during another portion of the regimen.
The regimen of 9 including a pulse of periodic dosages wherein said one or more one or more agents downregulate expression of one or more TGF-β isoforms in the ovarian epithelium to a greater extent during one portion of the regimen than during another portion of the regimen.
A pharmaceutical composition comprising one or more agents, said composition made by the process of selecting said one or more agents based on the ability of said one or more agents to alter the ratio of one or more TGF-β isoforms in the ovarian epithelium to one or more other TGF-β isoforms in the ovarian epithelium.
A method for designing a pharmacological composition comprising treating ovarian epithelial cells with a first progestin;
- testing said progestin-treated cells using microarray technology;
- identifying one or more biomarkers relevant to ovarian epithelial cancer prevention based on the expression altered by progestin action;
- treating normal ovarian epithelium cells with one or more candidate pharmacological agents;
- testing said candidate agent-treated cells with microarray technology for alteration of said one or more surrogate biomarkers;
- and selecting said candidate agents based on such tests.
Dependencies are inferred from the claim text.